Cancer therapy using cldn6 target-directed antibodies in vivo

An anti-claudin 6 (CLDN6) antibody selected from the group consisting of

• (i) an antibody produced by a hybridoma deposited under the accession no. DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), or DSM ACC3057 (GT512muMAB 5F2D2),
• (ii) a humanized or chimerized form of said antibody,
• (iii) an antigen binding fragment of said antibody, and
• (iv) a synthetic form of said antibody;
• wherein the antibody or fragment of (i), (ii), (iii), and (iv) is capable of binding to CLDN6 having the amino acid sequence of SEQ ID NO:
• 2 or SEQ ID NO:
• 6, or having the amino acid sequence encoded by SEQ ID NO:
• 1;
• and
• wherein the antibody or fragment of (i), (ii), (iii), and (iv), without an attached therapeutic effector moiety, when administered to a patient having a tumor characterized by tumor cells expressing CLDN6 inhibits growth of the tumor by binding to CLDN6.

An anti-claudin 6 (CLDN6) antibody selected from the group consisting of

• (i) an antibody produced by a hybridoma deposited under the accession no. DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), or DSM ACC3057 (GT512muMAB 5F2D2),
• (ii) a humanized or chimerized form of said antibody,
• (iii) an antigen binding fragment of said antibody, and
• (iv) a synthetic form of said antibody;
• wherein the antibody or fragment of (i), (ii), (iii), and (iv) is capable of binding to CLDN6 and binds to an epitope within SEQ ID NO:
• 2 or SEQ ID NO:
• 6, or to an epitope within SEQ ID NO:
• 3 and/or SEQ ID NO:
• 5, or to an epitope within an amino acid sequence encoded by SEQ ID NO:
• 1;
• and wherein the antibody or fragment of (i), (ii), (iii), and (iv), without an attached therapeutic effector moiety, when administered to a patient having a tumor characterized by tumor cells expressing CLDN6 inhibits growth of the tumor by binding to CLDN6.

An anti-claudin 6 antibody selected from the group consisting of:

• (i) an antibody produced by a hybridoma deposited under the accession no. DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), or DSM ACC3057 (GT512muMAB 5F2D2);
• (ii) a humanized or chimerized form of the antibody under (i);
• and
• (iii) an antigen binding fragment of the antibody under (i) or (ii).